With one likely blockbuster on the market in Eylea and at least three others in development, Regeneron Chief Scientific Officer Dr. George Yancopoulos has plenty to keep him busy for the next several years. Read the full feature >>
Two years after leaving the biotech giant Genzyme, Henri Termeer has found increased demand for his expertise and personal resources from a growing crowd of startups in the Boston area and The Netherlands, he told FierceBiotech in an interview. Read more >>
The R&D numbers for the top 10 biotechs may only amount to a fraction of what you'll find in Big Pharma. But unlike the giants, which are trying to keep a lid on multibillion-dollar budgets, you'll find a much faster crowd when you turn your gaze to the biotechs.
Last year AstraZeneca's MedImmune did about 20 biologics deals, not counting the academic pacts it assembled. Bahija Jallal, head of R&D, tells FierceBiotech there will be no letup in talent scouting: "If we do as little or more than last year, I would be happy."
Industry Voices is a platform for life sciences professionals to provide their particular view of a current technology, industry, or business topic. Here are our guidelines and submission process.
I've got a busy schedule of events coming up over the next few months. First, if you're headed to Chicago for BIO later this month, I hope you'll come by my executive breakfast. The big challenge in drug development now is figuring out how to do much faster, more efficient clinical drug programs. -- John Carroll, Editor-in-Chief. Follow me on Twitter.
Our readers hunger for context and analysis of major developments in the industry. We work hard to deliver such insights in all of our daily reports. Yet we aim to go deeper into stories with additional feature articles and special reports.
Today two countries on opposite sides of the world took radically different stances on pharma patents that will have a big impact on the future of drug R&D.
I'll be sitting down with four top R&D executives from some of the biggest pharma operations around the globe next month to see where we go from here. I hope to see you there. And if you sign up today, you can still get the early-bird special. The price goes up tomorrow. You can register here.